Hepatitis Diagnostic And Treatment Market Size, Share, Opportunities, And Trends By Type (Diagnosis, Blood Test, DNA Test, Liver Biopsy, RNA Testing, Liver Ultrasound, Treatment, Drugs, Injectable Alpha Interferons, Liver Transplant), By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), And By Geography - Forecasts From 2025 To 2030

Hepatitis Diagnostic and Treatment Market Size:

The Hepatitis Diagnostic And Treatment Market is expected to grow from USD 33.224 billion in 2025 to USD 39.915 billion in 2030, at a CAGR of 3.74%.

Hepatitis means inflammation of the liver. There are several hepatitis viruses that have been categorized as Hepatitis A, B, C, D, E, and G and among them, hepatitis A, B, and C are the most common. According to World Health Organization’s global hepatitis report 2017, hepatitis B and C are responsible for 96% of all hepatitis mortality. The rising number of hepatitis infected population, growing consumption of alcohol and drugs, and improved accessibility to hepatitis drugs are the major factors that are driving the market’s growth. New developments taking place in the treatment of the hepatitis virus, and global players expanding their footprint across geographies to provide medication for the disease are the factors that will boost the hepatitis diagnostic and treatment market growth.

Hepatitis Diagnostic and Treatment Market Segmentation Analysis:

• By Type

By type, the hepatitis diagnostic and treatment market has been broadly segmented into diagnostic and treatment. The hepatitis virus is diagnosed through various methods such as blood tests, DNA tests, Liver biopsies, RNA testing, and liver ultrasound and is treated with drugs, injectable alpha interferons, and in adverse cases liver transplant. Hepatitis B and C are considered as chronic viral hepatitis that are treated via antiviral medicines and injected alpha interferons.

• By Disease Type

By disease type, the hepatitis diagnostic and treatment market has been segmented into Hepatitis A, B, C, and others. Others include Hepatitis D, E, and G. Hepatitis B and C are the most spread diseases around the world.  Hepatitis B is endemic in China and eastern Asia where most people become infected during childhood.

• By Geography

Geographically, the hepatitis diagnostic and treatment market has been segmented into North America, Europe, the Middle East & Africa, Asia-Pacific, and South America region. North America accounts for the major share in the market owing to the advanced health infrastructure, accessibility of new drugs  and growing awareness among people about the disease.

Hepatitis Diagnostic and Treatment Market Competitive Intelligence:

The hepatitis diagnostic and treatment market is competitive owing to the presence of major players and regional vendors in the market. The global key players are Novartis AG, F. Hoffmann-La Roche Ltd, Merk & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead, Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc.

Segmentation

The hepatitis diagnostic and treatment market has been analyzed through the following segments:

• By Type
  • Blood Test
  • DNA Test
  • Liver Biopsy
  • RNA Testing
  • Liver Ultrasound
  • Treatment
  • Drugs
  • Injectable alpha Interferons
  • Liver Transplant
• By Disease Type
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indoensia
    • Thailand
    • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

5.1. Introduction

5.2. Blood Test

5.3. DNA Test

5.4. Liver Biopsy

5.5. RNA Testing

5.6. Liver Ultrasound

6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TREATMENT

6.1. Introduction

6.2. Drugs

6.3. Injectable alpha Interferons

6.4. Liver Transplant

7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE

7.1. Introduction

7.2. Hepatitis A

7.3. Hepatitis B

7.4. Hepatitis C

7.5. Others

8. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Siemens AG

10.2. F.Hoffmann La-Roche

10.3. Abbott Laboratories

10.4. DiaSorin S.p.A

10.5. bioMeriuex

10.6. MedMira, Inc.

10.7. Bio-Rad Laboratories

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Siemens AG

F.Hoffmann La-Roche

Abbott Laboratories

DiaSorin S.p.A

bioMeriuex

MedMira, Inc.

Bio-Rad Laboratories